What is Mazdutide 5MG & 10MG

Mazdutide 5MG & 10MG is a synthetic dual-receptor agonist targeting both the GLP-1 (Glucagon-Like Peptide-1) and Glucagon receptors, studied in research for the treatment of severe obesity and metabolic dysfunction. It is intended exclusively for research use.

Regarding its chemical identity, Mazdutide has a molecular formula of C172H263N43O53 and a molecular weight of ~3800 g/mol. Its reported canonical sequence is Synthetic Dual Agonist Analogue. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Mazdutide.

Product for research use.

Mechanism of action of Mazdutide

Mazdutide activates GLP-1 receptors to stimulate insulin secretion, delay gastric emptying, and suppress appetite. Simultaneously, it activates Glucagon receptors in the liver and adipose tissue to increase energy expenditure, promote lipolysis, and reduce hepatic steatosis.

Pharmacokinetics and pharmacodynamics of Mazdutide

Engineered with a fatty acid modification to extend its half-life, allowing for once-weekly administration in in vivo models. The dual activation must be carefully balanced to prevent the hyperglycemic effects of glucagon from overwhelming the hypoglycemic effects of GLP-1.

Scientific evidence on Mazdutide

The available evidence on Mazdutide is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Currently under heavy investigation in clinical trials (specifically by Innovent Biologics/Eli Lilly) as a next-generation weight loss drug. Preclinical models indicate it may produce greater weight loss and liver fat reduction than selective GLP-1 agonists.

Mazdutide applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Mazdutide protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Mazdutide, so no trial schemes or quantities are specified.

The presentations of this product (5MG & 10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Mazdutide

As a general guideline for laboratory handling, lyophilized peptides such as Mazdutide are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 5MG & 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Mazdutide Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Mazdutide security profile

The documented safety information in open sources for Mazdutide is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Because it stimulates the glucagon receptor, there are theoretical risks of transient increases in heart rate and potential hepatotoxicity if unbalanced. Common incretin side effects like severe nausea and gastrointestinal distress are frequently reported in models.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Mazdutide in a comparative context

Compared to Liraglutide (GLP-1 only) or Tirzepatide (GLP-1/GIP), Mazdutide introduces Glucagon receptor agonism. This uniquely targets the direct burning of energy (lipolysis and thermogenesis) rather than just reducing caloric intake.

History and development of Mazdutide

Developed as part of the “twincretin” and tri-agonist wave of metabolic research following the massive success of Semaglutide. It aims to replicate the metabolic state of starvation without actual caloric deprivation.